Drug Type Small molecule drug |
Synonyms ABK, Arbekacin, Arbekacin sulfate (JP17) + [5] |
Target |
Action inhibitors |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (28 Sep 1990), |
Regulation- |
Molecular FormulaC22H46N6O14S |
InChIKeyUTUVRPOLEMRKQC-XDJMXTNXSA-N |
CAS Registry104931-87-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01523 | Arbekacin Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hemorrhagic Septicemia | Japan | 28 Sep 1990 | |
Pneumonia | Japan | 28 Sep 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pneumonia, Bacterial | Phase 1 | United States | 01 Sep 2015 |
Not Applicable | - | 50 | Aminoglycosides (AGs) | dcwyftgaru(fndccpzlod) = ozutrryvqw tsegkbfvbn (dhsdgsvezo ) | Positive | 01 Feb 2012 | |
Glycopeptides (GPs) | dcwyftgaru(fndccpzlod) = rwzxkpvahh tsegkbfvbn (dhsdgsvezo ) |